295 results
8-K
EX-10.1
WINT
Windtree Therapeutics Inc
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
withdrawal or replacement, safety alert, warning, “dear doctor” letter, investigator notice, or other notice or action relating to an alleged or potential … lack of safety or efficacy of any product or Potential Product of the Company, any alleged product defect of any product or Potential Product
8-K
EX-2.1
WINT
Windtree Therapeutics Inc
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
.
Products; Safety and Efficacy
Section 3.9.
Inventory
Section 3.10.
Absence of Litigation
Section 3.11.
Brokers
Section 3.12.
Taxes
Section 3.13 … Authority outside the U.S.).
Section 3.8. Products; Safety and Efficacy. No product liability claim has been made against Seller relating to or resulting
8-K
EX-1.1
2meqj91v8pyoul
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
424B5
4rpoc1 tud7i2z2dje7
9 Nov 23
Prospectus supplement for primary offering
4:11pm
8-K
EX-99.1
vylcy
15 May 23
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
4:24pm
8-K
EX-1.1
ebh3bk nu
24 Apr 23
Entry into a Material Definitive Agreement
4:40pm
424B4
0ej1fwq 5a
20 Apr 23
Prospectus supplement with pricing info
6:03pm
8-K
EX-99.1
73mfdwnu2zgy k6u
3 Apr 23
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates
7:25am